Predictability of disease progression in amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 34, Issue 6, 2006, Pages 702-708

  Czaplinski, Adam ^a   Yen, Albert A ^b   Simpson, Ericka P ^b   Appel, Stanley H ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Amyotrophic lateral sclerosis (ALS); Disease progression; Outcome predictors; Primary endpoint; Therapeutic trials

Indexed keywords

RILUZOLE;

ADULT; AGE; AGED; AMYOTROPHIC LATERAL SCLEROSIS; APPEL ALS SCORE; ARTICLE; COVARIANCE; DISEASE COURSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SYMPTOM; UNIVARIATE ANALYSIS;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SICKNESS IMPACT PROFILE;

EID: 33845372864     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20658     Document Type: Article

References (35)

1. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
2. Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 2000;23:874-882.
3. Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 1999;22:1571-1575.
4. BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999;52:1427-1433.
5. Brinkmann JR, Andres P, Mendoza M, Sanjak M. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 1997;147:97-111.
6. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:96-107.
7. Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, et al. Can we eliminate placebo in ALS clinical trials? Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:11-15.
8. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
9. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
10. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006;77:390-392.
11. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;6:813-819.
12. Gordon PH, Miller RG, Moore DH. ALSFRS-R as a primary outcome measure in ALS clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 1):90-93.
13. Haverkamp LJ, Appel SH, Appel V. Natural history of ALS in a database population: validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
14. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology 2005;64:38-43.
15. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology 1997;49:1621-1630.
16. Lange DJ, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology 1996;47(suppl 2):S93-S94.
17. Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998;55:93-96.
18. Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
19. Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:84-98.
20. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 1997;152(suppl 1):S10-S17.
21. Lyall RN, Polkey M, Leigh P, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001;124:2000-2013.
22. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709-714.
23. Marti-Fabregas J, Dourado M, Sanchis J, Miralda R, Pradas J, Illa I. Respiratory function deterioration is not time-linked with upper-limb onset in amyotrophic lateral sclerosis. Acta Neurol Scand 1995;92:261-264.
24. Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:107-117.
25. Miller RG, Moore DH Jr, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
26. Mitsumoto H, Gordon P, Kaufmann P, Gooch CL, Przedborski S, Rowland LP. Randomized control trials in ALS: lessons learned. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 1):8-13.
27. Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, Holden D, et al. Onset, natural history and outcome in idiopathic motor neuron disease. J Neurol Sci 1993;118:48-55.
28. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751-755.
29. Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, et al. Survival prediction in sporadic amyotrophic lateral sclerosis: age and clinical form at onset are independent risk factors. Neuroepidemiology 1996;15:153-160.
30. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316-1322.
31. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 1998;50:66-72.
32. The ALS CNTF Treatment Study (ACTS) Phase III Study Group. A double-blind placebo controlled trial of subcutaneous recombinant human ciliary neurotrophic factor (rH-CNTF) in amyotropic lateral sclerosis. Neurology 1996;46:1244-1249.
33. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57:1171-1176.
34. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME, and the NEALS Consortium. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004;63:1933-1935.
35. Yen AA, Simpson E, Haverkamp LJ, Appel SH. AALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 1):94-98.